Oral Azacitidine Prolongs Survival of Patients With AML in Remission Independent of MRD Status
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status
Blood 2022 Apr 07;139(14)2145-2155, GJ Roboz, F Ravandi, AH Wei, H Dombret, F Thol, MT Voso, AC Schuh, K Porkka, I La Torre, B Skikne, J Zhong, CL Beach, A Risueño, DL Menezes, G Ossenkoppele, H DöhnerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.